# US 2010/0168086 A1 · 7,8,10,10a-tetrahydro-6h-benzo[c]chromen-9(6ah)-one modulators of cannabinoid receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168086 A1
- Document ID: US20100168086A1
- Status: Published application
- Kind: A1
- Application number: 12/565,034
- Filed: 2009-09-23
- Published: 2010-07-01
- Earliest claimed: 2008-09-25
- Assignees: Auspex Pharmaceuticals, Inc.
- Inventors: Thomas G. Gant; Manoucherhr M. Shahbaz
- Web page: https://patentgrep.com/patent/US20100168086A1

## CPC

- C07D 311/80: Dibenzopyrans; Hydrogenated dibenzopyrans
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/451: having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/616: by carboxylic acids, e.g. acetylsalicylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/02: for peripheral neuropathies
- A61P 25/20: Hypnotics; Sedatives
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to new 7,8,10,10a-tetrahydro-6H-benzo[c]chromen-9(6aH)-one modulators of cannabinoid receptors, pharmaceutical compositions thereof, and methods of use thereof.

## Claims

### Claim 1

A compound of structural Formula I
or a salt thereof, wherein:
R1-R36 are independently selected from the group consisting of hydrogen and deuterium; and
at least one of R1-R36 is deuterium.

### Claim 2 (depends on 1)

The compound as recited in claim 1 wherein at least one of R1-R36 independently has deuterium enrichment of no less than about 10%.

### Claim 3 (depends on 1)

The compound as recited in claim 1 wherein at least one of R1-R36 independently has deuterium enrichment of no less than about 50%.

### Claim 4 (depends on 1)

The compound as recited in claim 1 wherein at least one of R1-R36 independently has deuterium enrichment of no less than about 90%.

### Claim 5 (depends on 1)

The compound as recited in claim 1 wherein at least one of R1-R36 independently has deuterium enrichment of no less than about 98%.

### Claim 6 (depends on 1)

The compound as recited in claim 1 wherein said compound has a structural formula selected from the group consisting of

### Claim 7 (depends on 1)

The compound as recited in claim 1 wherein said compound has a structural formula selected from the group consisting of

### Claim 8 (depends on 7)

The compound as recited in claim 7 wherein each position represented as D has deuterium enrichment of no less than about 10%.

### Claim 9 (depends on 7)

The compound as recited in claim 7 wherein each position represented as D has deuterium enrichment of no less than about 50%.

### Claim 10 (depends on 7)

The compound as recited in claim 7 wherein each position represented as D has deuterium enrichment of no less than about 90%.

### Claim 11 (depends on 7)

The compound as recited in claim 7 wherein each position represented as D has deuterium enrichment of no less than about 98%.

### Claim 12 (depends on 7)

The compound as recited in claim 7 wherein said compound has the structural formula:

### Claim 13 (depends on 7)

The compound as recited in claim 7 wherein said compound has the structural formula:

### Claim 14 (depends on 7)

The compound as recited in claim 7 wherein said compound has the structural formula:

### Claim 15 (depends on 1)

A pharmaceutical composition comprising a compound as recited in claim 1 together with a pharmaceutically acceptable carrier.

### Claim 16 (depends on 1)

A method of treatment of a cannabinoid receptor-mediated disorder comprising the administration of a therapeutically effective amount of a compound as recited in claim 1 to a patient in need thereof.

### Claim 17 (depends on 16)

The method as recited in claim 16 wherein said disorder is selected from the group consisting of chemotherapy-induced emesis, neuropathic pain, fibromyalgia, multiple sclerosis, and insommnia.

### Claim 18 (depends on 16)

The method as recited in claim 16 further comprising the administration of an additional therapeutic agent.

### Claim 19 (depends on 18)

The method as recited in claim 18 wherein said additional therapeutic agent is selected from the group consisting of anti-emetics and analgesics.

### Claim 20 (depends on 19)

The method as recited in claim 19 wherein said analgesic is selected from the group consisting of carbamazepine, gabapentin, pregabalin, acetaminophen, acetylsalicyclic acid, ibuprofen, and naproxen.

### Claim 21 (depends on 19)

The method as recited in claim 19 wherein said anti-emetic is selected from the group consisting of dolasetron, granisetron, ondansetron, tropisetron, and palonosetron, domperidone, droperidol, haloperidol, chlorpromazine, promethazine, prochlorperazine, metoclopramide, alizapride, cyclizine, diphenhydramine, dimenhydrinate, meclizine, promethazine, hydroxyzine, dronabinol, midazolam, lorazepam, hyoscine, dexamethasone, aprepitant, casopitant, trimethobenzamide, and propofol.

### Claim 22 (depends on 16)

The method as recited in claim 16, further resulting in at least one effect selected from the group consisting of:
a. decreased inter-individual variation in plasma levels of said compound or a metabolite thereof as compared to the non-isotopically enriched compound;
b. increased average plasma levels of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;
c. decreased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;
d. increased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound; and
e. an improved clinical effect during the treatment in said subject per dosage unit thereof as compared to the non-isotopically enriched compound.

### Claim 23 (depends on 16)

The method as recited in claim 16, further resulting in at least two effects selected from the group consisting of:
a. decreased inter-individual variation in plasma levels of said compound or a metabolite thereof as compared to the non-isotopically enriched compound;
b. increased average plasma levels of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;
c. decreased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;
d. increased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound; and
e. an improved clinical effect during the treatment in said subject per dosage unit thereof as compared to the non-isotopically enriched compound.

### Claim 24 (depends on 16)

The method as recited in claim 16, wherein the method effects a decreased metabolism of the compound per dosage unit thereof by at least one polymorphically-expressed cytochrome P450 isoform in the subject, as compared to the corresponding non-isotopically enriched compound.

### Claim 25 (depends on 24)

The method as recited in claim 24, wherein the cytochrome P450 isoform is selected from the group consisting of CYP2C8, CYP2C9, CYP2C19, and CYP2D6.

### Claim 26 (depends on 16)

The method as recited claim 16, wherein said compound is characterized by decreased inhibition of at least one cytochrome P450 or monoamine oxidase isoform in said subject per dosage unit thereof as compared to the non-isotopically enriched compound.

### Claim 27 (depends on 26)

The method as recited in claim 26, wherein said cytochrome P450 or monoamine oxidase isoform is selected from the group consisting of CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP2G1, CYP2J2, CYP2R1, CYP2S1, CYP3A4, CYP3A5, CYP3A5P1, CYP3A5P2, CYP3A7, CYP4A11, CYP4B1, CYP4F2, CYP4F3, CYP4F8, CYP4F11, CYP4F12, CYP4×1, CYP4Z1, CYP5A1, CYP7A1, CYP7B1, CYP8A1, CYP8B1, CYP11A1, CYP11B1, CYP11B2, CYP17, CYP19, CYP21, CYP24, CYP26A1, CYP26B1, CYP27A1, CYP27B1, CYP39, CYP46, CYP51, MAOA, and MAOB.

### Claim 28 (depends on 16)

The method as recited in claim 16, wherein the method reduces a deleterious change in a diagnostic hepatobiliary function endpoint, as compared to the corresponding non-isotopically enriched compound.

### Claim 29 (depends on 28)

The method as recited in claim 28, wherein the diagnostic hepatobiliary function endpoint is selected from the group consisting of alanine aminotransferase (“ALT”), serum glutamic-pyruvic transaminase (“SGPT”), aspartate aminotransferase (“AST,” “SGOT”), ALT/AST ratios, serum aldolase, alkaline phosphatase (“ALP”), ammonia levels, bilirubin, gamma-glutamyl transpeptidase (“GGTP,” “γ-GTP,” “GGT”), leucine aminopeptidase (“LAP”), liver biopsy, liver ultrasonography, liver nuclear scan, 5′-nucleotidase, and blood protein.

### Claim 30 (depends on 1)

A compound as recited in claim 1 for use as a medicament.

### Claim 31 (depends on 1)

A compound as recited in claim 1 for use in the manufacture of a medicament for the prevention or treatment of a disorder ameliorated by the modulation of cannabinoid receptors.
